Psychedelic‐assisted therapy considered ‘breakthrough’ treatment for PTSD
Mental Health Weekly May 17, 2021 DOI: 10.1002/mhw.32791 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Peer reviewed |
|---|---|
| Population | Patients with severe, chronic post-traumatic stress disorder |
| Topics | Psychedelic-assisted therapy PTSD |
| Keywords | PTSD Treatment Trauma therapy Chronic PTSD Relief Symptom reduction Psychedelic-assisted sessions Drug-assisted treatment Hallucinogen therapy Innovative approach Psychiatric care Mental wellness Behavioral health Mental healthcare advancement Medical innovation Groundbreaking therapy Therapeutic advancement Medical breakthrough Healthcare innovation |
| Citations | 1 |
| Key points | Psychedelic-assisted therapy shows promise for severe, chronic PTSD and could move toward FDA approval. |
Abstract
New research involving the use of psychedelic‐assisted therapy is showing promise and significant implications for patients with severe, chronic post‐traumatic stress disorder (PTSD) and could potentially move the needle further toward Food and Drug Administration (FDA) approval, say researchers from the Multidisciplinary Association for Psychedelic Studies (MAPS).